DURHAM, N.C.–(BUSINESS WIRE)–Nuventra Pharma Sciences is pleased to announce the addition of Iftekhar Mahmood, Ph.D., to its growing team of experienced consultants. Dr. Mahmood has more than 25 years of clinical pharmacology experience at the FDA.
Dr. Mahmood worked in both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). During this period, Dr. Mahmood worked on neurological products, therapeutic proteins, coagulation factors, and immunoglobulins. Dr. Mahmood helped establish a robust clinical pharmacology program in the Office of Blood Review and Research (OBRR) and the Office of Tissue & Advanced Therapeutics (OTAT). In CBER, he led a team of clinical and preclinical pharmacologists for two years. Dr. Mahmood was the member of several working groups in CDER and CBER which wrote guidances for the pharmaceutical industry. He received three research grants from CDER for conducting research in the area of anti-epilepsy drugs, pediatric clinical pharmacology, and drug-drug interaction.
While at the FDA, in addition to his review duties, Dr. Mahmood was involved with clinical pharmacology research (both small and large molecules) and published more than 100 research papers in peer-reviewed scientific journals. His research mainly focused in allometric scaling, modeling, sparse sampling, and pediatric drug development. Dr. Mahmood also wrote and edited several scientific books.
“Dr. Mahmood is an exciting addition to the Nuventra team,” said Geoffrey Banks, Ph.D., Nuventra’s CEO, adding further, “His wealth of experience within CDER and CBER at the FDA will be a valuable resource for our clients.”
Nuventra is the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services. Nuventra gives pharmaceutical companies and CROs rare access to a hands-on team of industry-leading consultants experienced in complex studies and analyses. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic and pharmacometric principles and making them understandable and usable for common sense drug development. Read more at www.nuventra.com.